WO2011072320A1 - Effervescent l-carnitine-based composition - Google Patents
Effervescent l-carnitine-based composition Download PDFInfo
- Publication number
- WO2011072320A1 WO2011072320A1 PCT/AU2009/001619 AU2009001619W WO2011072320A1 WO 2011072320 A1 WO2011072320 A1 WO 2011072320A1 AU 2009001619 W AU2009001619 W AU 2009001619W WO 2011072320 A1 WO2011072320 A1 WO 2011072320A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carnitine
- composition
- effervescent
- approximately
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
Definitions
- This invention relates to an effervescent composition containing L-carnitine (levocarnitine) and to a method of manufacturing said composition.
- the invention concerns an effervescent composition which effectively masks the off-notes and poor taste normally associated with L-carnitine as well as reducing 'fishy' odours and flatulence normally resulting from L-carnitine ingestion and metabolism.
- Carnitine is a quaternary ammonium compound having the following chemical structure:
- the biologically active form is the isomer L-carnitine, which is essential for energy production and fat metabolism in birds, fish and mammals.
- L- carnitine plays a role in the transportation of long-chain fatty acids across the inner mitochondrial membrane during the breakdown of fats and lipids, resulting in the generation of metabolic energy in the form of ATP.
- L-carnitine is widely sold and used as an orally taken dietary supplement for treating various physiological conditions, and in particular for reducing body fat, enhancing lean muscle mass, fighting fatigue and increasing stamina.
- L-carnitine is a highly hygroscopic compound, the preparation of oral formulations containing L-carnitine and the storage of such formulations has been problematic.
- L-carnitine based oral formulations Another problem with known L-carnitine based oral formulations is that L- carnitine has an unpleasant odor and unpleasant taste, which are both difficult to mask.
- L-carnitine as a dietary supplement
- Trimethylamine has a 'fishy' odour and as a result of the metabolism of the L-carnitine, some individuals taking L-carnitine may develop a 'fishy' odor in their breath and sweat. A build-up of 'fishy' gas in the bowel can also result, leading to flatulence.
- L-carnitine when taken orally in an effervescent form/composition (which preferably creates an acidic environment when in solution), can reduce the physiological problems normally observed with L-carnitine ingestion and metabolism, namely 'fishy' odour and flatulence.
- the inventors have also discovered that the effervescent form/composition, particularly when further containing a sweetening agent and/or flavouring agent, can effectively mask the off-notes and poor taste normally associated with L-carnitine.
- the inventors have further discovered that the effervescent form/composition is less problematic to prepare and store than other types of L-carnitine compositions as it tends to be less hygroscopic.
- the invention concerns an effervescent L-carnitine based composition for treating a physiological condition yet minimising a physiological problem normally resulting from L-carnitine metabolism, said composition comprising: an effective amount of L-carnitine for treating said physiological condition; and effervescent agents.
- an effervescent L-carnitine based composition for treating a physiological condition yet minimising a physiological problem normally resulting from L-carnitine metabolism, said composition comprising: an effective amount of L-carnitine for treating said physiological condition; and effervescent agents for creating an acidic environment when the composition is in solution.
- L-carnitine any suitable amount and form of L-carnitine may be used in the composition, provided that it is ingestable and can provide the desired physiological effect.
- the L-carnitine may be in the form of a free base or salt.
- any suitable types and amounts of effervescent agents may be used in the composition. Typically, this will be a combination of at least one type of acid and base.
- the acid may be one or more of the following: citric, malic, tartaric, adipic, and fumaric acid.
- the composition comprises approximately 15-40 % w/w anhydrous citric acid, and more preferably about 29% w/w.
- the base may be one or more of the following: sodium bicarbonate, potassium bicarbonate, sodium carbonate and potassium carbonate.
- the composition comprises approximately 10-30% w/w sodium bicarbonate, and more preferably about 19% w/w.
- the acid environment has a pH of approximately 4 to 5, and more preferably, a pH of about 4.7 (in 100 mL water) or 4.8 (200 mL water).
- the composition can further comprise a sweetening agent and/or flavouring agent for further masking the off-notes and poor taste normally associated with L-carnitine.
- a sweetening agent and/or flavouring agent for further masking the off-notes and poor taste normally associated with L-carnitine.
- Any suitable type and amount of sweetening agent and/or flavouring agent may be used.
- the sweetening agent may be a natural or artificial sweetener, or a mixture of both.
- the sweetening agent is a non-calorific natural sweetener such as stevia or sucralose.
- the composition comprises approximately 0.2-0.8% w/w sucralose, and more preferably about 0.4% w/w.
- the composition may be of any suitable form, including in the form of an effervescent powder, granule or tablet.
- the composition may be packaged in the form of a capsule.
- the capsule can be any suitable capsule known in the art, including hard or soft gelatine prepared from beef and/or pork gelatin.
- the capsule whether hard or soft, can be prepared from plant-based gelling substances so as to be suitable for persons on a vegetarian diet.
- Plant-based gelling substances suitable for the preparation of vegetarian capsules include carrageenans or modified forms of starch and cellulose.
- the composition may further comprise one or more of the following: a binding agent, buffering agent, disintegrating agent, lubricant, glidant and flow regulating agent.
- the composition may further comprise other types of ingredients such as, for example, a colouring agent.
- a colouring agent may be any suitable natural and/or artificial colouring agent.
- the composition comprises approximately 0.01- 0.3% w/w carminic acid (cochineal), and more preferably about 0.1% w/w.
- the effervescent L-carnitine based composition comprises: approximately 52.08%) w/w L-carnitine; approximately 28.65% w/w anhydrous citric acid; approximately 18.78% w/w sodium bicarbonate; approximately 00.39%) w/w sucralose; and approximately 00.10% w/w cochineal.
- a method of treating a physiological condition of an individual with an effervescent L-carnitine based composition yet minimising a physiological problem normally resulting from L- carnitine metabolism by the individual comprising the step of orally administering to the individual an effervescent L-carnitine based composition comprising: a physiologically effective amount of L-carnitine for treating said physiological condition; and effervescent agents, preferably for creating an acidic environment when the composition is in solution.
- a physiologically effective amount of L-carnitine in combination with effervescent agents for creating an acidic environment when the L-carnitine is in solution, in the preparation of a medicament (composition) for treating a physiological condition of an individual yet minimising a physiological problem normally resulting from L-carnitine metabolism by the individual.
- the composition may be used to treat any suitable type of physiological condition.
- the composition may be used to reduce body fat, enhance lean muscle mass, fight fatigue and increase stamina.
- the physiological problem normally observed with L-carnitine ingestion and metabolism may be the 'fishy' odour of the individual's sweat or breath or flatulence.
- the composition is dissolved in water and ingested twice daily.
- approximately 3-4 g of the composition of the preferred embodiment described above is dissolved in 100-200 mL water and ingested twice daily (morning and afternoon).
- a method of preparing an effervescent L-carnitine based composition for treating a physiological condition yet minimising a physiological problem normally resulting from L-carnitine metabolism comprising the step of: blending an effective amount of L-carnitine for treating said physiological condition with effervescent agents, preferably for creating an acidic environment when the L-carnitine is in solution.
- the method further comprises the step of blending at least one sweetening agent with the effervescent agents prior to blending with L-carnitine.
- the effervescent agents are dried prior to addition to the sweetening agent or L-carnitine.
- the blending is undertaken in a low relative humidity (RH) environment, preferably at less than about 20% RH.
- the method further comprises the step of blending in a colouring agent.
- L-carnitine when taken orally in an effervescent form/composition, which preferably creates an acidic environment when in solution, can reduce the physiological problems normally observed with L-carnitine ingestion and metabolism.
- the inventors have also discovered that the effervescent form/composition, particularly when further containing a sweetening agent and/or flavouring agent, can effectively mask the off-notes and poor taste normally associated with L-carnitine.
- the inventors have further discovered that the effervescent form/composition is less problematic to prepare and store than other types of L-carnitine compositions as it tends to be less hygroscopic.
- the composition comprises L-carnitine in combination with the effervescent agents anhydrous citric acid and sodium bicarbonate, the sweetening agent sucralose, and the colouring agent carminic acid to colour the composition pink.
- the composition is preferably in powder form.
- the masking of the poor taste and off-notes of L-carnitine is believed to be provided by the citric acid and sodium bicarbonate combination, further enhanced by the sweetening agent sucralose.
- the stoichiometry of this combination when dissolved in water, creates a pleasant tasting and non-odourous solution that can be easily consumed.
- the effervescent agents produce an acidic environment when the composition is in solution, such as in water.
- the inventors believe that the effervescent agents produce a low pH environment in the portal circulation of the individual to whom the composition is administered.
- L-carnitine in 100 mL of tap water yielded a pH of 4.7
- L-carnitine in 200 mL of tap water yielded a pH of 4.8.
- Individuals who had been taking commercially available L-carnitine dietary supplements, such as the MusahiTM carnitine supplement, and then the composition as herein exemplified noted the differences in taste, smell and 'fishy' flatulence. In particular, individuals generally noted that the composition as herein exemplified was pleasant tasting and smelling, and removed the 'fishy' flatulence that resulted from taking commercially available supplements.
- a general procedure for the preparation of the L-carnitine based composition preferably entails the following steps:
- the resultant blend is formed into the appropriate form (powder, granulate or tablet) and packed relatively soon after preparation. It is particularly preferred for the packing to be undertaken within 5-8 hours of blending the composition.
- L-carnitine USP (260.40 kg) was dispensed in a controlled RH (no more than 30%) and temperature (no more than 25 °C) atmosphere.
- Step 2 Two batches of sodium bicarbonate BP (each of 46.95 kg) and citric acid BP (143.25 kg) were separately dried in an oven at 50 °C until the moisture content of each compound was no more than 0.3%. The compounds were then transferred to a controlled RH (no more than 30%) and temperature (no more than 25 °C) atmosphere.
- Step 3 One batch of sodium bicarbonate from Step 2 was sieved through a stainless steel mesh #22 with cochineal CI 75470 (0.25 kg) and sucralose USP (0.975 kg). The sieved materials were mixed for five minutes on a drum roller.
- the second batch of sodium bicarbonate from Step 2 was sieved through a stainless steel mesh #22 with cochineal CI 75470 (0.25 kg) and sucralose USP (0.975 kg). The sieved materials were mixed for five minutes on a drum roller.
- Step 8 The mixes resulting from Step 3 and Step 4 and the L-carnitine from Step 5 were combined and mixed for 5 minutes using a bin mixer. Step 8
- the citric acid from Step 6 was combined with the mix from Step 7 and mixed for ten minutes using a bin mixer. Five samples were removed and tested to ensure that the moisture content was not more than 0.5%. The blend was then mixed for a further five minutes using a bin mixer. A further five samples were removed and tested to ensure that the moisture content was not more than 0.5%.
- Step 10 Packing was undertaken in a controlled atmosphere of 15% RH and 20 °C into sachets containing 3.84 g of the effervescent composition.
- Each 3.84 g sachet comprised the following composition:
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2009356961A AU2009356961B2 (en) | 2009-12-14 | 2009-12-14 | Effervescent L-carnitine-based composition |
PCT/AU2009/001619 WO2011072320A1 (en) | 2009-12-14 | 2009-12-14 | Effervescent l-carnitine-based composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/AU2009/001619 WO2011072320A1 (en) | 2009-12-14 | 2009-12-14 | Effervescent l-carnitine-based composition |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011072320A1 true WO2011072320A1 (en) | 2011-06-23 |
Family
ID=44166633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2009/001619 WO2011072320A1 (en) | 2009-12-14 | 2009-12-14 | Effervescent l-carnitine-based composition |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2009356961B2 (en) |
WO (1) | WO2011072320A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI476016B (en) * | 2012-10-31 | 2015-03-11 | ||
CN111990574A (en) * | 2020-09-18 | 2020-11-27 | 内蒙古精晶生物科技有限公司 | L-carnitine nutritional effervescent tablet |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4968517A (en) * | 1986-10-22 | 1990-11-06 | Gerhard Gergely | Method for preparing an effervescent granulate, an effervescent granulate made accordingly |
WO1997000672A1 (en) * | 1995-06-23 | 1997-01-09 | Defelice Stephen L | Nutritional and/or dietary composition and method of using the same |
AU5778801A (en) * | 2000-08-14 | 2002-02-21 | Sphere Healthcare Pty Ltd | Improvements in effervescent tablet manufacture |
DE10119946A1 (en) * | 2001-04-24 | 2003-04-30 | Joachim Steuer | Addition of conjugated linoleic acid, creatine and/or L-carnitine to an effervescent tablet, useful for e.g. increasing muscle protein synthesis, increasing fat burnoff and increasing performance |
CN101439027A (en) * | 2008-12-19 | 2009-05-27 | 北京康比特体育科技股份有限公司 | Effervescent tablet containing L-carnitine-L-tartrate |
WO2009071954A1 (en) * | 2007-12-07 | 2009-06-11 | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | Effervescent tablets and effervescent granules containing carnitine tartrate |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19626315A1 (en) * | 1996-07-01 | 1998-01-15 | Jan Hes | Multireflex surface lighting system (MF) |
-
2009
- 2009-12-14 WO PCT/AU2009/001619 patent/WO2011072320A1/en active Application Filing
- 2009-12-14 AU AU2009356961A patent/AU2009356961B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4968517A (en) * | 1986-10-22 | 1990-11-06 | Gerhard Gergely | Method for preparing an effervescent granulate, an effervescent granulate made accordingly |
WO1997000672A1 (en) * | 1995-06-23 | 1997-01-09 | Defelice Stephen L | Nutritional and/or dietary composition and method of using the same |
AU5778801A (en) * | 2000-08-14 | 2002-02-21 | Sphere Healthcare Pty Ltd | Improvements in effervescent tablet manufacture |
DE10119946A1 (en) * | 2001-04-24 | 2003-04-30 | Joachim Steuer | Addition of conjugated linoleic acid, creatine and/or L-carnitine to an effervescent tablet, useful for e.g. increasing muscle protein synthesis, increasing fat burnoff and increasing performance |
WO2009071954A1 (en) * | 2007-12-07 | 2009-06-11 | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | Effervescent tablets and effervescent granules containing carnitine tartrate |
CN101439027A (en) * | 2008-12-19 | 2009-05-27 | 北京康比特体育科技股份有限公司 | Effervescent tablet containing L-carnitine-L-tartrate |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI476016B (en) * | 2012-10-31 | 2015-03-11 | ||
CN111990574A (en) * | 2020-09-18 | 2020-11-27 | 内蒙古精晶生物科技有限公司 | L-carnitine nutritional effervescent tablet |
Also Published As
Publication number | Publication date |
---|---|
AU2009356961A1 (en) | 2012-08-02 |
AU2009356961B2 (en) | 2016-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI517793B (en) | Contains the composition of imidazole peptides and quercetin glycosides | |
US20050271754A1 (en) | Composition for prevention or treatment of an alcohol hangover | |
JP2003504374A (en) | Bioavailable chelates of creatine and essential metals | |
US9572848B1 (en) | Composition of matter for sexual dysfunction | |
AU2020215729B2 (en) | Enhanced nitrate compositions and methods of use | |
JP5739659B2 (en) | Intestinal harmful substance adsorbent and method for producing the same | |
AU2009356961B2 (en) | Effervescent L-carnitine-based composition | |
JPH08503964A (en) | Dietary hypocholesterolemic composition | |
KR101721145B1 (en) | - Food composition including -Carnitine Magnesium Citrate for diet and promoting bowel movement | |
JP2008237058A (en) | Dietary supplement | |
CN111971065B (en) | Citrulline composition | |
US7189416B2 (en) | Method for stable and controlled delivery of (-)-hydroxycitric acid | |
JP3736776B2 (en) | New calcium composition | |
JP2004081010A (en) | Food composition | |
JPH01275522A (en) | Deodorant agent of body smell and uraroma, food and drink and table luxury of deororant for body smell and uraroma | |
JPH11116478A (en) | Preventing agent for obesity | |
ES2786774B2 (en) | Composition for NADH coenzyme compound, preparation and application thereof. | |
EP0326963B1 (en) | Deodorant as well as deodorizing food, drink and seasoning | |
JP7170771B2 (en) | oral composition | |
JP7170770B2 (en) | oral composition | |
CA3041914C (en) | Anaerobic antioxidant composition | |
RU2330428C1 (en) | Mineral iodised salt with lower sodium content | |
WO2003009840A1 (en) | Composition comprising at least one lipase inhibitor and carnitine | |
KR20240079544A (en) | Health functional food composition using arginin and manufacturing method of using thereof | |
JP2003063970A (en) | Anti-osteoporosis composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09852145 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009356961 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2009356961 Country of ref document: AU Date of ref document: 20091214 Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09852145 Country of ref document: EP Kind code of ref document: A1 |